Alnylam plunges as earnings deliver ‘one-two punch’
The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.